Literature DB >> 9486392

Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection.

B Kallinowski1, K Haseroth, G Marinos, C Hanck, W Stremmel, L Theilmann, M V Singer, S Rossol.   

Abstract

There is evidence that TNF-alpha contributes to the pathogenesis of chronic viral hepatitis. The cellular effects of this cytokine are regulated by two specific receptors, and membranous shedding of these receptors reflects activation of the TNF system. We performed a study of TNF-alpha and functionally active soluble TNF-receptors (TNFR-p55 and -p75) in 105 patients with chronic HCV infection. In HCV RNA-positive patients a significant enhancement of TNF-alpha and both receptor types was observed compared with controls (TNF-alpha 83.8+/-91.7 pg/ml versus 18.8+/-8.4 pg/ml, P<0.001; TNFR-p55 1.4+/-0.4 ng/ml versus 0.9+/-0.2 ng/ml, P<0.0001; TNFR-p75 6.4+/-2.4 ng/ml versus 2.9+/-0.6 ng/ml, P<0.0001, respectively). The enhanced serum levels of TNF-alpha and TNFRs were reflected by a significant expression of TNFR-specific mRNA in peripheral mononuclear cells of HCV-infected patients (P<0.001). Serum aminotransferases correlated with soluble TNFR-p75 (P<0.001) but not with TNFR-p55 and TNF-alpha. We demonstrated an association of the degree of histological inflammation with both TNFRs (P<0.01). Furthermore, enhanced hepatocellular expression of TNF-alpha and TNFRs could be demonstrated by immunohistochemical staining in HCV-infected patients. Sixty-eight out of 105 patients were treated with interferon-alpha (IFN-alpha) (3x10(6)U x 3/week). Pretreatment levels of TNF-alpha and TNFRs did not differ between responders and non-responders. Our results demonstrate that TNF-alpha and TNFRs are enhanced in chronic HCV infection and reflect histological activity of the disease. This up-regulation of TNFRs might modify host response and potentially contribute to liver damage in chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486392      PMCID: PMC1904907          DOI: 10.1046/j.1365-2249.1998.00469.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

Review 1.  Two TNF receptors.

Authors:  L A Tartaglia; D V Goeddel
Journal:  Immunol Today       Date:  1992-05

Review 2.  Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions.

Authors:  J Vilcek; T H Lee
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

3.  Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection.

Authors:  N Sheron; J Lau; H Daniels; J Goka; A Eddleston; G J Alexander; R Williams
Journal:  J Hepatol       Date:  1991-03       Impact factor: 25.083

4.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

5.  Corynebacterium parvum (Propionibacterium acnes): an inducer of tumor necrosis factor-alpha in human peripheral blood mononuclear cells and monocytes in vitro.

Authors:  S Rossol; R Voth; S Brunner; W E Müller; M Büttner; H Gallati; K H Meyer zum Büschenfelde; G Hess
Journal:  Eur J Immunol       Date:  1990-08       Impact factor: 5.532

6.  Serum levels of cytokines in chronic liver diseases.

Authors:  H Tilg; A Wilmer; W Vogel; M Herold; B Nölchen; G Judmaier; C Huber
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

7.  A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.

Authors:  C A Smith; T Davis; D Anderson; L Solam; M P Beckmann; R Jerzy; S K Dower; D Cosman; R G Goodwin
Journal:  Science       Date:  1990-05-25       Impact factor: 47.728

8.  Interleukin-1 alpha enhances hepatotoxicity of tumor necrosis factor-alpha in galactosamine-sensitized mice.

Authors:  J Nagakawa; I Hishinuma; K Hirota; K Miyamoto; M Yasuda; T Yamanaka; K Katayama
Journal:  Immunopharmacol Immunotoxicol       Date:  1991       Impact factor: 2.730

9.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

10.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.

Authors:  D Aderka; H Engelmann; Y Maor; C Brakebusch; D Wallach
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  30 in total

1.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Hepatitis C virus treatment complicated by rheumatoid arthritis.

Authors:  Meredith Borman; Mark G Swain
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

3.  Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritis.

Authors:  Alison B Jazwinski; Janet Jezsik; Stacy P Ardoin; Rex M McCallum; Hans L Tillmann
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

4.  Concomitant therapy of Crohn's disease and hepatitis C with budesonide and antivirals.

Authors:  Alok Gupta; Michael D Sitrin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

5.  Nuclear factor κB up-regulation of CCAAT/enhancer-binding protein β mediates hepatocyte resistance to tumor necrosis factor α toxicity.

Authors:  Yongjun Wang; Rajat Singh; Youqing Xiang; Linda E Greenbaum; Mark J Czaja
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

6.  Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels.

Authors:  Filiz Akyüz; Nuray Polat; Sabahattin Kaymakoglu; Nevzat Aksoy; Kadir Demir; Fatih Beşişik; Selim Badur; Yilmaz Cakaloglu; Atilla Okten
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

7.  Marked increase of serum hepatitis C virus (HCV) RNA titer during treatment with high-dose prednisolone in a case of polymyositis.

Authors:  Takashi Kato; Takahiro Okai; Takuya Shiroma; Junko Fukuda; Ryuichi Yokohari; Masao Tadokoro
Journal:  Clin Rheumatol       Date:  2004-11-30       Impact factor: 2.980

8.  Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.

Authors:  Sophia Li; Primal P Kaur; Virginia Chan; Steven Berney
Journal:  Clin Rheumatol       Date:  2009-03-17       Impact factor: 2.980

9.  Gene expression profiling and network analysis reveals lipid and steroid metabolism to be the most favored by TNFalpha in HepG2 cells.

Authors:  Amit K Pandey; Neha Munjal; Malabika Datta
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

10.  Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4.

Authors:  Abdel-Rahman N Zekri; Hanaa M Alam El-Din; Abeer A Bahnassy; Naglaa A Zayed; Waleed S Mohamed; Suzan H El-Masry; Sayed K Gouda; Gamal Esmat
Journal:  Comp Hepatol       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.